Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis

IMPORTANCE: The high cost of biologics used to treat cancer has been an increasing burden in the world. In China, the recent approval of cancer biosimilar drugs to resolve this problem is promising, but evidence of clinical benefits, price, and uptake for these drugs is still lacking. OBJECTIVES: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Xingxian, Du, Xin, Li, Zhuangqi, Liu, Jingwen, Lv, Xufeng, Li, Haoran, Guo, Qixiang, Wang, Cen, Xue, Xuecai, Le, Kaidi, Jiang, Xiaomeng, Huang, Lin, Yang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570888/
https://www.ncbi.nlm.nih.gov/pubmed/37824143
http://dx.doi.org/10.1001/jamanetworkopen.2023.37348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570888/
https://www.ncbi.nlm.nih.gov/pubmed/37824143
http://dx.doi.org/10.1001/jamanetworkopen.2023.37348

Ejemplares similares